GlassScriptPhysician profile
Sonia Jamil
NPI 1003182833
$1,465.46
in general payments reported to CMS, 2019-2025
17 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $70.81 · 2021: $36.26 · 2022: $122 · 2023: $15.92 · 2024: $718 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $206.65 | 2020-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $186.30 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $174.57 | 2024-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $166.98 | 2023-2025 | Farxiga, Airsupra |
| Abbvie INC. | $146.51 | 2021-2025 | |
| Esperion Therapeutics, INC. | $122.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $86.39 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $71.84 | 2024 | |
| Mallinckrodt Hospital Products INC. | $66.31 | 2024 | Acthar |
| Exact Sciences Corporation | $55.09 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.18 | 2024 | Jardiance, Synjardy |
| Renalytix Ai, INC. | $24.78 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Xeris Pharmaceuticals, INC. | $24.32 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $23.70 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.06 | 2025 | Purified Cortrophin Gel |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $22.04 | 2024 | |
| Novo Nordisk INC | $20.55 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.